Developing a new paradigm for cancer treatment
Excellamol is producing peptide-drug conjugates that directly target tumor microenvironment.
Self-Depot Platform
Excellamol’s Self-Depot platform is an innovative drug development technology for intralesional delivery of peptide-cell composites, biotherapeutics and peptide-drug conjugates.
